Immunotherapy for Type 1 Diabetes Safe in Small Study

Proinsulin peptide immunotherapy for newly diagnosed type 1 diabetes appeared safe and tolerable in a phase 1b safety clinical trial; it could be used like allergy desensitization in the future.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply